Table 2 CTL lines with preferential... | American Society of Hematology

Table 2

CTL lines with preferential cytolytic activity against hematopoietic target cells

ID	Class I HLA antigens (patient and donor)	CTL line	Percentage lysis of recipient B-LCL	Percentage lysis of donor B-LCL	Percentage lysis of recipient fibroblasts	HLA restricting allele	Estimated phenotype frequency of minor H antigen, percentage
1	A1, A2, B8, B55, C7, C3	4	40	4	2	B55	40
		6	34	6	2	A2	30
		8	45	7	6	B55	80
		13	58	5	7	B8	50
3	A1, A2, B8, B18, C7, C7	3	27	0	6	A1	< 10
3	A1, A2, B8, B18, C7, C7	5	24	0	8	A1	13
5	A24, A32, B35, B44, C4,C4	1	47	6	3	ND	< 10
		4	21	0	1	B35	30
		5	46	0	3	A32	< 10
		8	58	0	3	B44	28
		10	28	1	2	B44	36
6	A1, A3, B8, B49,C7, C7	3	25	5	1	B8	11
6	A1, A3, B8, B49,C7, C7	4	57	4	5	A1	50
7	A1, A68, B44, B55, C5, C3	1	22	1	1	A1	17
		2	33	0	2	B55	60
		3	43	0	1	A1	33
		6	41	0	2	ND	< 10
		7	39	0	6	A68	27
		8	29	0	0	B55	40
		10	29	0	7	A68	55
		11	40	0	2	A1	14
		13	29	0	0	B44	18
		14	27	0	2	B44	11
		15	22	0	4	ND	< 10
		16	38	2	0	B44	26
		19	31	1	8	C5	67
		21	40	0	4	ND	< 10
		22	45	0	1	A1	44
8	A2, A3, B7, B18, C7, C7	2	24	1	0	B7	78
8	A2, A3, B7, B18, C7, C7	4	77	1	3	B7	56
9	A1, A2, B8, B14, C7, C8	1	42	0	2	B8	10
		8	59	1	2	B8	20
		12	51	1	2	ND	< 10
		14	60	0	2	ND	< 10
10	A1, A2, B7, B27, C7, C2	1	47	7	0	B7	28
		3	26	4	1	A1	47
		4	46	1	0	B27	25
		7	37	1	0	ND	< 10
		8	37	4	0	A2	40
		9	25	4	3	B27	33
		10	39	7	8	B27	20
		13	54	2	1	A2	63
4	A2, A2, B7, B7, C7, C7	All CTL lines killed fibroblasts

ID	Class I HLA antigens (patient and donor)	CTL line	Percentage lysis of recipient B-LCL	Percentage lysis of donor B-LCL	Percentage lysis of recipient fibroblasts	HLA restricting allele	Estimated phenotype frequency of minor H antigen, percentage
1	A1, A2, B8, B55, C7, C3	4	40	4	2	B55	40
		6	34	6	2	A2	30
		8	45	7	6	B55	80
		13	58	5	7	B8	50
3	A1, A2, B8, B18, C7, C7	3	27	0	6	A1	< 10
3	A1, A2, B8, B18, C7, C7	5	24	0	8	A1	13
5	A24, A32, B35, B44, C4,C4	1	47	6	3	ND	< 10
		4	21	0	1	B35	30
		5	46	0	3	A32	< 10
		8	58	0	3	B44	28
		10	28	1	2	B44	36
6	A1, A3, B8, B49,C7, C7	3	25	5	1	B8	11
6	A1, A3, B8, B49,C7, C7	4	57	4	5	A1	50
7	A1, A68, B44, B55, C5, C3	1	22	1	1	A1	17
		2	33	0	2	B55	60
		3	43	0	1	A1	33
		6	41	0	2	ND	< 10
		7	39	0	6	A68	27
		8	29	0	0	B55	40
		10	29	0	7	A68	55
		11	40	0	2	A1	14
		13	29	0	0	B44	18
		14	27	0	2	B44	11
		15	22	0	4	ND	< 10
		16	38	2	0	B44	26
		19	31	1	8	C5	67
		21	40	0	4	ND	< 10
		22	45	0	1	A1	44
8	A2, A3, B7, B18, C7, C7	2	24	1	0	B7	78
8	A2, A3, B7, B18, C7, C7	4	77	1	3	B7	56
9	A1, A2, B8, B14, C7, C8	1	42	0	2	B8	10
		8	59	1	2	B8	20
		12	51	1	2	ND	< 10
		14	60	0	2	ND	< 10
10	A1, A2, B7, B27, C7, C2	1	47	7	0	B7	28
		3	26	4	1	A1	47
		4	46	1	0	B27	25
		7	37	1	0	ND	< 10
		8	37	4	0	A2	40
		9	25	4	3	B27	33
		10	39	7	8	B27	20
		13	54	2	1	A2	63
4	A2, A2, B7, B7, C7, C7	All CTL lines killed fibroblasts

CTL indicates cytotoxic T lymphocyte; B-LCL, Epstein-Barr virus–transformed lymphoblastoid cell line; and ND, not determined.